Harbin Pharmaceutical Group (600664.SH): Ferrous Protein Succinate obtains approval notice for chemical raw materials drug market application.
Haiyao Group Co., Ltd. (600664.SH) announced recently that its subsidiary, Ha Yao Group San Jing Ming Shui Pharmaceuticals Co., Ltd., has received the "Notice of Approval for the Market Application of Ferrous Succinate" from the National Medical Products Administration of China, with the document number 2026YS00100.
Harbin Pharmaceutical Group (600664.SH) announced that recently, its subsidiary, Ha Yao Group Sanjing Ming Shui Pharmaceutical Co., Ltd., received the "Chemical Raw Material Drug Market Approval Notification" for Ferrous Sucrose issued by the National Medical Products Administration [Number: 2026YS00100].
The approval of Ferrous Sucrose as a chemical raw material drug is an important development for the company in the field of raw materials, as it will allow the company to have independent control over related raw materials. At the same time, this approval will further solidify the company's integrated development strategy for raw material formulations, and will enrich the company's product structure.
Related Articles
HUABAO INTL (00336) spent HK$969,200 to repurchase 210,000 shares on February 5th.
Zhejiang Southeast Space Frame (002135.SZ) jointly won the bid for a cultural industry project worth 994 million yuan.
China Galaxy (06881) has completed the redemption of the 24th series of short-term financing notes due in 2025.
HUABAO INTL (00336) spent HK$969,200 to repurchase 210,000 shares on February 5th.
Zhejiang Southeast Space Frame (002135.SZ) jointly won the bid for a cultural industry project worth 994 million yuan.
China Galaxy (06881) has completed the redemption of the 24th series of short-term financing notes due in 2025.
